key: cord-1011236-8ign1drv
authors: Malhamé, Isabelle; D'Souza, Rohan; Cheng, Matthew P.
title: The Moral Imperative to Include Pregnant Women in Clinical Trials of Interventions for COVID-19
date: 2020-06-29
journal: Ann Intern Med
DOI: 10.7326/m20-3106
sha: d6700e4083d405108906a7b83df24b5c78ddc24d
doc_id: 1011236
cord_uid: 8ign1drv

Although the number of clinical trials for patients with COVID-19 is increasing, many exclude pregnant women as participants or do not address pregnancy. This commentary discuss why pregnancy women should be included in clinical trials of interventions for COVID-19.

In this first monthly update of our living review (1), we searched MEDLINE (Ovid) weekly from 4 May to 8 June 2020 using the same search strategy described in the original review, and we also identified additional citations from consultation with content experts. Searches yielded 138 results; independent dual review of these records identified 4 new studies (see Supplement Tables 1 and 2) and 2 in-progress trials for inclusion.

One new retrospective cohort study examined the association between angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) use and the likelihood of testing positive for COVID-19 (2). This study included all patients who had testing in 1 health system in 2 different states; patients with symptoms were prioritized for testing at the time so most patients were likely to have been symptomatic. As in the previous review that identified 3 similar studies, neither ACEI nor ARB use was associated with likelihood of testing positive for COVID-19.

This study also examined the association between ACEI or ARB use and COVID-19 illness severity. It found use of these medications was associated with a moderate increase in hospitalization and intensive care unit admission risk but not risk for mechanical ventilation (2). We found an additional 3 new studies evaluating the association between ACEI or ARB use and COVID-19 illness severity. Two were small single-center retrospective cohort studies from China that found that ACEI or ARB use was not associated with an increased risk for death or severe COVID-19 illness (3, 4) . A nationwide retrospective cohort study from Korea similarly found that these medications were not associated with severity of illness after adjustment for demographic characteristics, comorbid conditions, and hospital type (5) .

The 2 studies from China included small, highly select patient populations and did not describe in detail how ACEI or ARB exposure was determined. The 2 larger studies were generally methodologically sound, although 1 study cautioned that the number of patients treated with ACEI or ARBs who had the outcomes of intensive care unit admission or mechanical ventilation was small (2) . (See Supplement Table 3 for methodological strengths and weaknesses of the studies.)

Of note, 1 international study that examined the association between ACEI or ARBs and severity of COVID-19 illness has since been retracted by the journal in which it was published (6) . We will no longer consider results of this study in determining overall effects or certainty of evidence.

Overall, the addition of the new studies and the retraction of 1 prior study does not change the findings or certainty of evidence ratings we reported in the original review.

We identified 2 randomized controlled trials, currently in progress, that will compare the effects of continuing or withdrawing ACEI or ARB treatment on clinical outcomes in patients hospitalized with COVID-19. One is a U.S. study (7) and the other is a Brazilian study (8) , and both are expected to be completed by the end of 2020.

Risks and impact of angiotensinconverting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults

Association of use of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19)

Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication

The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension

Association of renin-angiotensinaldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study

Retraction: cardiovascular disease, drug therapy, and mortality in covid-19

Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019 (REPLACECOVID)

Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19 (BRACE-CORONA)

This article was published at Annals.org on 25

Annals of Internal Medicine 1